22 results about "Myositis" patented technology

Provided herein are method for identifying a subject as having or at risk of having myocarditis and / or myositis based on the detection of the level of cytotoxic CD8+ T-cells and / or inflammatory myeloid cells, and / or on the detection of the level of expression of a TNF signaling via NFκB, an interferon-α signaling, an interferon-γ signaling, an IL2 / STAT5 signaling, a hypoxia signaling and / or a complement signaling in CD45+ immune cells. The identification of such patients is used in methods of treating a subject having or at risk of having myocarditis and / or myositis, methods of treating cancer, and methods of treating immune checkpoint therapy (ICT)-related myocarditis and / or ICT-related myositis. The methods of treatment include the administration of a therapeutic compound to inhibit IL-1β and TNF.

The present invention provides: a compound which is an antisense oligonucleotide capable of regulating the expression of a RasGRP4 gene and treating myositis and rheumatoid arthritis, and which has a nucleic acid base sequence consisting of 8-80 linked nucleosides and comprising at least 8 consecutive nucleic acid bases complementary to a transcript of RasGRP4; or a pharmacologically acceptable salt thereof.

Provided is a non-human autoimmune disease model animal derived from an immunodeficient non-human animal as a pathologic model animal in which symptoms of an autoimmune disease are more faithfully reproduced, wherein peripheral blood mononuclear cells (PBMCs) derived from a heterologous animal subjected to CD8-positive T cell removal treatment are transfected, and symptoms of an autoimmune disease are exhibited.

Provided herein are methods of treating myositis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. Also provided herein are FcRn antagonists for use in the treatment of myositis, and for use in the manufacture of a medicament for the treatment of myositis.

The invention discloses a liver-protecting and lipid-lowering traditional Chinese medicine beverage, which comprises a beverage, the beverage comprises 18g of coffee and 8g of paraphlonia, and distilled water, and relates to the technical field of traditional Chinese medicine beverages. Coffee and paraphlonia are combined, so that homology of medicine and food is achieved, and the effect of effectively lowering lipid is achieved. According to the conventional lipid-lowering scheme used at present, statins are used, however, adverse reactions such as myalgia, myositis, new diabetes mellitus and abnormal liver function are likely to occur after the statins are taken for a long time, drug intervention standards are not met, however, by using the golden sophora japonica coffee, lipid can be effectively lowered while the dietary structure is adjusted, and almost no side effect exists; the product can be used for a long time and can reduce risk factors of hyperlipidemia. Coffee not only has a lipid-lowering effect, but also can reduce the total-factor death rate by reducing the heart rate through habitual intake of coffee, and high-quality paraphlonia and pure Yunnan small-grain coffee are selected as paraphlonia coffee, so that mellow and rich taste can be ensured, and patients can easily insist on taking the paraphlonia coffee.

The present invention provides biomarkers for predicting immune-related myasthenia gravis, myocarditis, and myositis. The key locus HLA-DQB1 * 03: 03 is obtained through HLA typing, and the method has a good prediction value on whether tumor patients subjected to ICI treatment suffer from irMG and / or myositis and myocarditis or not. The invention provides a screening tool which can identify a potential high-risk irAE patient before ICI treatment, and provides inspiration for preventive treatment development of irMG susceptible people.

The present application relates to compounds of formula (A), wherein R1 is selected from formula (II) and formula (III) and R2 is selected from formula (IV), formula (V) and formula (VI), as IRAK4 inhibitors for use in methods of treating, for example, asthma and chronic obstructive pulmonary disease (COPD), cancer, inflammatory diseases and autoinflammatory / autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjogren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis. Preferred compounds of the present application are, for example: N-(imidazo[l,2-b]pyridazin-3-yl)-l-cyclohexyl-2H-indazole-5-carboxamide, N-(pyrazolo[l,5-a]pyrimidin-3-yl)-l-cyclohexyl-2H-indazole-5-carboxamide, N-(imidazo[l,2-b]pyridazin-3-yl)-l-azaspiro[4.5]dec-8-yl-2H-indazole-5-carboxamide and N-(pyrazolo[l,5-a]pyrimidin-3-yl)-l-azaspiro[4.5]dec-8-yl-2H-indazole-5-carboxamide derivatives. An exemplary compound of the present application is, for example: N-(imidazo[l,2-b]pyridazin-3-yl)-6-methoxy-2-((5r,8r)-l-methyl-2-oxo-l-azaspiro[4.5]dec-8-yl)-2H-indazole-5-carboxamide (Example 1): formula (VII).

The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1β, TNF-α, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

The present invention provides a compound which is, as an antisense oligonucleotide that controls the gene expression of RasGRP4 and is capable of treating myositis and rheumatoid arthritis, an antisense oligonucleotide having a nucleobase sequence that contains 8-80 consecutive nucleosides and has at least eight continuous nucleobases which are complementary to a transcript of RasGRP4, or a pharmaceutically acceptable salt thereof.

The invention discloses a TIF1 gamma recombinant antigen and a preparation method and application thereof, compared with an existing antigen, an antigen site of the TIF1 gamma recombinant antigen is more fully exposed, then the sensitivity and specificity of TIF1 gamma antibody detection can be improved, the antigen is applied to diagnosis of cancer-related myositis, and the sensitivity and specificity of cancer-related myositis are improved. And the sensitivity and the accuracy can be greatly improved. Meanwhile, the TIF1gamma recombinant antigen also improves the problem that the full-length TIF1gamma antigen is easy to precipitate, and has important significance for improving the antigen expression quantity, expanding the production application of the antigen and reducing the production cost.

The invention provides a method for constructing a myositis-related interstitial lung disease mouse model, which comprises the following steps: injecting 10 micrograms of ODN2395 into the abdominal cavity of a female BALB / c mouse, injecting 0.25 mL of a mixed emulsion of SD (Sprague Dawley) rat skeletal muscle homogenate and a complete Freund's adjuvant into each of the two sides of the back of the female BALB / c mouse at the same time point, and feeding for a certain time to obtain a film-formed mouse. The method has the advantages that raw materials are easy to obtain, and the modeling method is simple; 2, the modeling time is relatively short; and 3, the model forming rate is high, and the method is more in line with the pathogenesis and pathological phenotype of IIM-ILD.

The application belongs to the technical field of medicine, and particularly relates to the use of icariin in the preparation of lipid-lowering drugs with muscle protection. In view of the adverse reactions such as myalgia and myositis caused by the existing statins in the lipid-lowering process, the muscle protection effect of icariin in the lipid-lowering process is evaluated by constructing a high-fat cell model and a high-fat Caenorhabditis elegans model. It is found through research that icariin can significantly reduce the content of triglyceride, total cholesterol and lipid droplet accumulation in high-fat cells, reduce the content of triglyceride and lipid droplet accumulation in high-fat C. elegans, and prolong the lifespan of high-fat C. elegans. Further research shows that icariin can improve the muscle state of high-fat C. elegans while lowering lipid, and the specific performance is the enhancement of the movement ability of C. elegans and the maintenance of the structural integrity of body wall muscle fibers. The application discloses the unique advantage of icariin in the lipid-lowering process, that is, the muscle protection effect, and can solve the adverse reactions such as myalgia and myositis caused by the existing statins, and has an important clinical application prospect.

Formula (I) compounds are selective inhibitors of histone deacetylase 6 (HDAC6) for treating, for example, peripheral neuropathy, graft rejection, GVHD, myositis, diseases associated with lymphocyte dysfunction, multiple myeloma, non-Hodgkin's lymphoma, autoimmune diseases, inflammatory diseases, cancer and neurodegenerative diseases. Preferred compounds are, for example, 2-(4-((5-(benzo[b]thiophene-3-yl)-1H-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and related compounds.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The invention relates to a protein related to a rapid progression type interstitial lung disease, a detection kit and application thereof, and provides a biomarker of connective tissue disease (CTD) combined with rapid progression type pulmonary interstitial fibrosis (RPILD), which can be used for diagnosis of rapid progression type pulmonary interstitial fibrosis (RPILD) combined with connective tissue diseases such as myositis, scleroderma and the like.

The present invention relates to a pharmaceutical compound or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of the following conditions, wherein the pharmaceutical compound or a pharmaceutically acceptable salt thereof is characterized in that it simultaneously inhibits autotaxin (ATX) and agonizes PPARγ, and has a chemical formula selected from the group consisting of formulas (A), (B), (C), (D), (E), (F), (G), and (H): a) fibroproliferative diseases, in particular interstitial lung diseases (ILD) and / or liver diseases such as all types of hepatitis and / or non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH) and / or cirrhosis, where the ILD is a primary disease, preferably idiopathic pulmonary fibrosis and / or sarcoidosis and / or interstitial pneumonia, or where the ILD is associated with an autoimmune and / or inflammatory and / or metabolic disease, preferably rheumatoid arthritis-ILD ​​and / or scleroderma-ILD and / or myositis-ILD ​​and / or diabetes-ILD ​​and / or cardiovascular disease-ILD combination, and / or b) an inflammatory and / or autoimmune disease, preferably rheumatoid arthritis and / or scleroderma, and / or c) cancer, in particular lung cancer and / or hepatocellular carcinoma and / or pancreatic cancer and / or glioblastoma and / or neuroblastoma, and / or d) metabolic diseases, in particular type 1 diabetes and / or type 2 diabetes and / or obesity [Formula 1] TIFF2026503883000014.tif94126

This invention provides the application of small molecule peptides AWR and / or LQR in the preparation of drugs for treating myositis-associated interstitial lung disease (IIM-ILD), belonging to the field of biomedical technology. By comparing the distribution levels of metabolites in the serum of healthy volunteers and IIM-ILD patients, this invention found that two small molecule peptides, alanine-tryptophan-arginine (AWR) and leucine-glutamine-arginine (LQR), were significantly reduced in IIM-ILD patients. Subsequently, by using AWR and LQR in IIM-ILD model mice, it was determined that AWR and LQR can significantly slow down the loss of body weight and multiple pathological indicators such as lung damage in IIM-ILD mice, and reduce the relative expression levels of various inflammatory factors, making them potential clinical drug candidates for IIM-ILD.

To provide a pharmaceutical composition for preventing or treating myositis.SOLUTION: The present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1β, TNF-α, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.SELECTED DRAWING: Figure 20

The present disclosure relates to compositions and methods for treating diseases (e.g., myositis diseases and disorders) in a subject in need thereof using anti-ILT7 antibodies or antigen-binding fragments thereof.

This invention discloses a recombinant TIF1γ antigen, its preparation method, and its applications. Compared to existing antigens, the antigenic sites of this recombinant TIF1γ antigen are more fully exposed, thereby improving the sensitivity and specificity of anti-TIF1γ antibody detection. Applying this antigen to the diagnosis of cancer-associated myositis can significantly improve sensitivity and accuracy. Furthermore, this recombinant TIF1γ antigen also addresses the issue of easy precipitation of the full-length TIF1γ antigen, which is significant for increasing antigen expression levels, expanding antigen production and applications, and reducing production costs.

Provided herein are methods of treating myositis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist, in particular efgartigimod. Also provided herein are FcRn antagonists (in particular efgartigimod) for use in the treatment of myositis and for use in the manufacture of a medicament for the treatment of myositis.